Life Sciences Archive » May, 2019

Life Sciences - May, 2019

329 articles

• J&J Rep Grilled On 'Low Abuse Potential' Opioid Claim
• Heritage Pharma Admits Price Fixing, Aids DOJ Probe
• 4 Firms Break From Pack In Robust May For IPOs
• Claims Rep For J&J Talc Supplier Survives Removal Bids
• From Prison, Shkreli Files $30M Suit Over Retrophin Ouster
• Health Hires: Morgan Lewis, Manatt Phelps, Dovel Tech
• FDA Focus: What Covington's Practice Chair Is Watching
• Pharma Co. Gets Suit Over $61M Offering Sent To Mass.
• J&J Hit With $300M Punitive Damages Verdict In NY Talc Trial
• The Role Of Risk Aversion In Reverse-Payment Agreements
• LA County Sues Monsanto, Pfizer Unit Over PCB Pollution
• J&J Targeted Docs To Push Fentanyl Patch, Okla. Judge Hears
• DOJ Requires Divestitures In $6.8B Amcor-Bemis Tie-Up
• Dilworth Paxson Adds Ex-Reed Smith IP Atty In NJ, Pa.
• Pharma Co., Founder To Pay $7M Over Aspirin Drug Fraud
• NJ AG Latest To Go After Sacklers Over Opioid Crisis
• Deals Rumor Mill: Hansoh, CBS-Viacom, Gannett
• TridentUSA Lender Says Loan Fight Breaks Restructuring Deal
• Novum Keeps Sale Option Open As Ch. 11 Plan Talks Progress
• Hatch-Waxman Presuit Considerations For Generics: Part 2
• 'Ashamed' NECC Pharmacist Spared Prison In Meningitis Case
• Motherhood & Making Partner: The View From 2 BigLaw Moms
• J&J Glossed Over Opioid Dangers, Okla. Judge Hears
• J&J, Colgate Expert Defends Talc Products As Trial Nears End
• Caster Semenya Appeals Testosterone Ruling To Swiss Court
• 2 Firms Named Lead Counsel In Trevena Stock-Drop Suit
• 5 Attorneys On Being The Only Woman In The Room
• Millennials Are Pushing Back Against Law Firm Sexism
• Toy Race Car Co. Owner Accused Of $4M Aspirin Drug Fraud
• Insurer Says $3.3M TCPA Deal Excluded From Lab's Policy
• Ex-NECC Pharmacist Gets 2.5 Years For Role In Drug Fraud
• University Of California Gets 5th CRISPR Patent
• Allergan Looks To Have Shire's Eye Drug Suit Tossed Again
• Law Profs Back Bid For High Court Input In ERISA Suit Venue
• Breaking Down The Proposal For A Patent Eligibility Revamp
• UFC Fighter Wins $27.5M Over Mislabeled Supplement
• Drugmaker Aqua Will Pay $3.5M To Settle Kickback Claims
• And Now A Word From The Panel: Why Not Just Arbitrate?
• Shareholders Say Boston Is Best For $555M Perrigo Fraud Suit
• Hatch-Waxman Presuit Considerations For Generics: Part 1
• Attys In $11.9M Thoratec Heart Device Deal Seek $2.9M In Fees
• Last-Minute Deals Delay Argos' Ch. 11 Confirmation
• Pomerantz To Lead Securities Suit Against WuXi
• How FDA Is Refreshing Its Recall Readiness Guidance
• 3 Law Firm Business Tactics To Support A Niche Practice
• Prosthetics Co. Can't Shirk Atty Fees In Patent Dispute
• FDA Rolls Eyes At Drug Co.'s 'Financial Distress' Claim
• Atty Fees Aren't USPTO 'Expenses': Fed. Circ. Bar To Justices
• Can You Spot The Gender Disparity? A Guide To Implicit Bias
• In The March Toward Parity, Law Firms Fall Behind
• The Best Law Firms For Female Partners
• J&J's 2nd Mistrial Bid 'Ridiculous,' Calif. Judge Says
• Ancestry.com Gets Health Info Privacy Suit Sent To Arbitration
• Blue Cross' Antitrust Suit Belongs In NJ, Janssen Says
• Reed Smith Atty's Widow Can't Take GSK Fight To High Court
• Attys Behind Syphilis Study Suit Fight Sanctions Bid
• Pharmaceutical Antitrust Legislation To Watch
• J&J Called Architect Of Opioid Crisis As Epic Trial Begins
• New Opinions Highlight 3 FMLA Issues To Avoid
• Lessons From Red Yeast Rice May Inform FDA's Path For CBD
• The Best Law Firms For Female Attorneys
• Glass Ceiling Slow To Break For Female Attys In 2018
• What 12 Gender Bias Complaints Say About BigLaw
• Teva Settles Okla. Opioid Case For $85M Just Before Trial
• J&J Can't Get New Trial After $29.5M Talc Verdict
• Chancery Saves Ligand From $3.75B Loss On Bond Bungle
• Pharma Co. Inks $22M Deal Ending Opioid Reporting Claims
• Meet The Attorneys Facing Off In The Oklahoma Opioid Trial
• McKesson Enjoyed 'Massive Insider Trading Binge,' Suit Says
• What Attys Need To Know As Landmark Opioid Trial Begins
• UK Litigation Roundup: Here's What You Missed In London
• FCA Suit Against Ex-Aegerion Execs Is Likely To Live On
• Class Attys Get $1M Fees In TCPA Deal Over Unwanted Faxes
• Real-Life Lessons For Lawyers From 'Game Of Thrones'
• Biopharma Co. Advicenne Plans Cross-Listing In Brussels
• 5 Tips To Help Your Summer Associates Succeed
• 'Roundup Cocktail' Argument A Potent Threat After $2B Award
• Aegerion Pharma's Interim Ch. 11 Cash Request Irks Judge
• J&J, Colgate Duck Sanctions After Expert Blows Past Order
• FTC Says Likely Pay-For-Delay Deals Are Down
• BioChemics Can't Revive SEC Probe Coverage Bid At 1st Circ.
• 2nd Circ. OKs $2.7M In Fees From BioScrip Investor Deal
• 2 Biotech Cos. Raise $111M Combined In Low-Priced IPOs
• Fountain Healthcare's Third Fund Hits €118M First Close
• Chemical Co. Misled Investors Before IPO, Investor Suit Says
• Avenatti Booted From Class Counsel In Surgical Gown Suit
• Keys To Communicating A Law Firm's Mission
• Endo Investors Seek Class Cert. In Opioid Stock-Drop Suit
• What's Ahead For FDA Regulation Of Dietary Supplements
• New Views On Statistical Significance Affect Expert Testimony
• Kenneth Feinberg Tapped To Mediate Monsanto Roundup MDL
• TridentUSA Ch. 11 Lender Fight Over Priority Claims Heats Up
• Chancery Finds Ex-CEO In Contempt In Biopharma IP Suit
• Judge Grows Weary Of Infighting In J&J Talc Supplier's Ch. 11
• Draft Patent Eligibility Bill Would Undo Alice, Mayo
• GSK, Teva Urge 3rd Circ. To Nix Lamictal Class Cert.
• Pharmas Want Verdict Axed To Settle IP, Antitrust Disputes
• Amgen Says Rival Used Trade Secrets To Poach 14 Reps
• Ex-Olympus Exec Ducks Prison In Tainted Scopes Case
• Nivea Maker Can't Duck Suit Claiming Lotion Was A Drug
• Amgen Lobs $167M Bid For Danish Biopharma Nuevolution
• Purdue's Sacklers Pushed Opioids To Get Rich, New Suits Say
• Solicitor General Tells Justices To Skip Roche Patent Appeal
• Second Atty Sanctioned For Monsanto MDL Opening Remark
• House Lawmakers Joust Over Drug Pricing Transparency Bills
• Torrent Pharma Accused Of Distributing Tainted Pills
• J&J Unit Hit With Antitrust Suit Over 'Sham' Zytiga Patent
• CVS Defends Contract Counterclaim In Sentry Antitrust Suit
• Ex-J&J Safety Exec Warned Against Speechifying In Talc Trial
• Feds' Rebate Switch May Cost Mallinckrodt $600M, Suit Says
• Grant & Eisenhofer, Wolf Popper To Lead AbbVie Records Suit
• J&J Hit With $25M NY Talc Verdict, But Wins Trial In SC
• J&J Tells 7th Circ. Missing FDA Evidence Dooms $20M Verdict
• How Lawyers Can Help Save The Planet
• Time To Create A Viable Path To Biosimilar Interchangeability
• Justices Lay Out Failure To Warn 'Clear Evidence' Standard
• Aegerion Files Ch. 11, Plans $400M Sale To Amryt Pharma
• Merck Buys Peloton Therapeutics For $1.05B Ahead Of IPO
• Pradaxa User Wins $542K Verdict In Conn. Bellwether Trial
• USPTO Tells Justices Law Is Clear-Cut On Win-Or-Lose Fees
• Houston Pharma Co. To Recall Contaminated And Weak Drugs
• J&J Loses Mistrial Bid Over Curious Judge
• Dexcom Asks Fed. Circ. To Nix $1.3M Fee Award In IP Row
• Drugmaker, Retailers Strike Deal In Loestrin Antitrust MDL
• Alcor Looks To Overturn $6.5M Blood Testing IP Verdict
• Union Of Tech, Life Sciences And Health Care Is Here To Stay
• High Court Won't Hear Orexigen Securities Fraud Suit
• Justices Say Judges, Not Juries, Must Decipher FDA Rules
• A Potential New Fight Over FTC's 13(b) Authority
• Texas Judge Backs Broad DOJ Authority To End FCA Suits
• Orexigen Cleared For Wind Down After Del. Ch. 11 Confirmed
• CVS Ditches False Ad Suit Over Joint Health Pills
• Dysfunction Leads Del. Chancery To Dissolve Pharma Co.
• House Passes Bill To Lower Drug Prices, Bolster ACA
• 8 Firms Steer 5 IPOs Topping $1B Led By Diamondback Unit
• How Supreme Court Conservatives Have Shaped The FCA
• IRS Should Use Tax Law To Combat The Opioid Epidemic
• J&J Hit With $80M Verdict In Philly Mesh Case
• American Researchers To Be Added To Nobel-Related Patents
• FTC Must Tackle Anti-Competitive Drug Rebate Practices
• Dorsey & Whitney Adds Veteran Product Liability Litigator
• Zetia Buyers Demand Info On Generics In Pay-For-Delay Suit
• Inside The New FCA Cooperation Credit Guidelines
• Key Takeaways From Roundup Verdicts So Far
• A Chat With Gilead Sciences Legal Ops Leader Gary Tully
• Trump Ditches New Negotiating Powers For Medicare Part D
• CDC's HIV Prevention Patents Invalid, Gilead CEO Tells House
• United, Humana Say Classes Can't Carve Up Generic Awards
• Blood Clot Drug Buyers Must Redo Class Cert. Bid
• Ill. Court Kills Shunt Patent Suit That Targeted Hundreds
• Essure Users Fight To Keep Bayer Injury Suits Alive In Calif.
• 5th Circ. Revives MD's Securities Suit Against Ex-Biz Partner
• Pa. Justices Suggest Juries Should Decide Risperdal Time Bar
• New Leader Can't Save Biotech IPO Suit, Judge Rules
• FDA Response To Cannabidiol Confusion Is Slow And Steady
• Deals Rumor Mill: Helaba-DekaBank, Pret A Manger, Takeda
• 5 More States Target Purdue Pharma Over Opioid Marketing
• Allergan Wins Just $48.5K At Trial Over Imprimis False Ads
• Pyrinas-Aeneas JV Eyes $120M Biotech Real Estate Fund
• $2B Roundup Verdict Likely Won't Hold Up, Legal Pros Say
• Imprimis Owes Rival Allergan False Ad Drug Profits, Jury Told
• North Dakota To Appeal Dismissal Of Purdue Opioid Suit
• DLA Piper Announces New Artificial Intelligence Practice
• Ixchel To 9th Circ. In Biogen Row: Companies Are People, Too
• Insurers Flag Special Counsel In Imerys Ch. 11
• SEC's Relaxed Audit Rules Likely To Get Mixed Reviews
• Interest Groups Slam Pa. Ruling Over Cancer-Pesticide Link
• Fed. Circ. Kills 2 Patents On Horizon Pain Drug Vimovo
• USPTO Leaves It Up To Applicants To Flag Patent Term Errors
• Fla. Blue Says DaVita Charity Scheme Cost Insurer Millions
• Gene Sequencing Co. ArcherDX Scores $60M Funding Round
• Why I Became A Lawyer: Completing The Journey Home
• 3 Firms Steer New Takeda, Frazier Biopharma Venture
• NJ Justices Deny Merck Shareholder's Docs Request
• Gilead Built HIV Drug Empire On 'No Generic' Deals, Suit Says
• Pa. AG Says Purdue Buried Doctors In False Painkiller Claims
• Fed. Circ. Backs PTAB Ax Of J&J Prostate Cancer Drug Patent
• What Fed. Circ. False Ad Ruling Means For Section 337 Claims
• Boehringer Waves White Flag In Humira Patent Battle
• Roche Again Delays $4.3B Spark Buy Amid Regulatory Review
• Diabetes-Focused Biotech Prices $40M IPO Well Below Range
• J&J Hid Asbestos In Talc For Years, Latest Jury Told In SC
• Fed. Circ. Backs Novartis In Kidney Cancer Drug Patent Case
• ViSalus, Class Spar Over Potential $925M Robocall Award
• Attys React To High Court FCA Statute Of Limitations Ruling
• Identity Politics: How Firms Seal The Deal After A Merger
• High Court Got It Right On FCA Time Limits
• No Health Supplement IP Infringement, Fed. Circ. Affirms
• 3 Biotech Firms Prime IPOs That Could Raise $285M Total
• The Dangers Of BigLaw's Merger-Happy Growth Strategy
• Some IP Boutiques Take Hit Amid Shifting Patent Landscape
• The Firms That Lost The Most Attorneys In 2018
• Challenges To Different Patents Not Serial, PTAB Says
• J&J, Teva Lose Last-Ditch Bids To Avoid Okla. Opioid Trial
• Allergan Says Asacol Buyers' Generic-Delay Suit Defective
• Lannett Hit With Del. Suit Over Generic-Drug Price-Fixing
• Teva A 'Consistent Participant' In Drug Price-Fixing, AGs Say
• Monsanto Hit With $2B Verdict In 3rd Roundup Trial
• Judging A Book: Wood Reviews 'The Making Of A Justice'
• New Biotech ElevateBio Brings In $150M From Investors
• Insys Faces $18M Bill For Final Stretch Of Founder's Trial
• High Court Extends Time Limit For Nonintervened FCA Cases
• Megafirms Drive Thirst For Tie-Ups As Firms Scale Up
• These Law Firms Keep Their Partnership Ranks Lean
• Law360 Reveals 400 Largest US Firms
• FDA Eases Way For Gold-Standard Biosimilars
• Gilead Must Face Bulk Of Patients' Suit Over HIV Drugs
• Texas Justices End Dallas Newspaper Defamation Suit
• Fresenius Beats Fired Worker's Age Discrimination Suit
• Reed Smith Nabs Ex-Baker McKenzie Arbitration Pro In NY
• FDA Draft Guidance On Medical Device Inspections Is Limited
• Ex-Abiomed Exec Asks 1st Circ. To Revive $5M Bonus Suit
• Steptoe Lures FDA Compliance Pro From Keller Heckman
• Loeb & Loeb-Led Blank Check Co. IPO Raises $100M
• Getting Out Of Legal Project Management Debt
• How The New FCA Cooperation Credit Guidelines Fall Short
• SEC Won't Take Action Against Ocular Over Eye Drug
• Bipartisan Bill Aims To Deem Pharma Tactics Anti-Competitive
• 7 Cos. Price IPOs Totaling $689M Led By Russian Job Biz
• Fenwick & West Adds Startup-Focused Orrick Benefits Atty
• J&J Can't Transfer 2,400 Talc Suits To Del. Fed. Court
• Iancu Tells Congress One Drug Can Deserve Many Patents
• Novartis Inks $5.3B Deal To Get Eye Drug From Takeda
• Ex-Abbott Researcher Can't Duplicate Termination Claims
• Perrigo Inks $750M Deal As Part Of Shift To Consumer Goods
• Nabriva Hit With Stock-Drop Suit Over FDA Drug Rejection
• Drug Cos. Call 'Blocking Patent' Rule An 'Existential Threat'
• Latham Steers Boston Scientific's $465M Spinal Device Deal
• 6 Ways To Keep Your Jury From Zoning Out
• House Unanimously Passes Bills On Drug Patent Listings
• FCA Cooperation Guidance Still Missing Key Details
• FDA 'Heatstick' OK Clouds Agency's Youth Vaping Campaign
• 'Punish' Monsanto With $1B Roundup Verdict, Calif. Jury Told
• 6 Highlights As Trump Demands Drug Prices In TV Ads
• BakerHostetler Fights 'Indefensible' DQ In Opioid MDL
• Bernstein Liebhard Gets Lead Spot In Alnylam Stock Drop Suit
• Fed. Circ.'s Mayo Interpretation Spot On, Clinic Says
• Walgreens Board Says It Reacted Quickly To Theranos Fraud
• Fed. Circ. Says Sandoz Biosimilars Don't Step On Amgen IP
• Merck Legally Denied Union Workers Day Off, NLRB Says
• Deals Rumor Mill: Novartis, Permira, Grab
• GTx Framed Oncternal Takeover As Acquisition, Investors Say
• Arnold & Porter Leads Pfizer Deal Worth Up To $810M
• 5 Ways To Enhance Patent Strategy With Data Analytics
• Ex-Purdue Prez Said Addicts Are Victimizers, Not Victims: Suit
• DOJ Unveils Cooperation Credit Checklist For FCA Targets
• Fed. Circ. Zeroes In On Holes In Prenatal Testing Patent
• Senate Committee Seems United On Drug Pricing Reform
• HHS Must 'Unscramble The Egg' On Billions In Drug Cuts
• Prosthetic Maker Must Unwind Acquisition, FTC Judge Says
• Bayer CropScience Says Fired Scientist Stole Trade Secrets
• Squire Patton Taps Ex-MoFo IP Vets With Drug Co. Experience
• Atty Must List Conflict Info Before Guiding Future Talc Claims
• Chemical Co. Wants Pension Claims Cut From ERISA Suit
• Express Scripts Class Can't Revive Anthem Disclosure Suit
• IP Trade Group Urges Justices To Ax 'Blocking Patent' Rule
• Biotech Trevi Nabs $70M In Revised IPO, Private Placement
• New Regs, New Tech Bring New Medical Device Cyber Liability
• Workers Can't Get Colgate Sanctioned Over 'Sham Witness'
• 5 Myths In Legal Crisis Communications
• Key Takeaways From New 2nd Circ. Pleading Standards
• Insys Jurors Say They Thought Execs Were Guilty Early On
• 1st Circ. Flips $34M FCA Award To New Whistleblower
• NJ Pharma Co. Can Solicit Votes On Ch. 11 Plan
• Monsanto Can't Bring EPA's Latest Report Into Roundup Trial
• Teary Plaintiff Tells Jury About Painful Cancer In J&J Talc Trial
• MabVax Therapeutics Lines Up $3.7M Ch. 11 Asset Sale
• Judge Questions United's Bid For New Pay-For-Delay Experts
• Amarin Says Attys 'On Speed Dial' After Ending Omega-3 Suits
• Apotex, Fresenius Kabi Settle Amgen's Cancer Drug IP Suit
• Ill. Sterilization Plant Can't Fight Closure In Federal Court
• Aralez Ch. 11 Liquidation Plan Gets Court's Approval
• Pomerantz Nabs Lead In Aveo Pharma Stock-Drop Suit
• Avenatti Blasts Class Counsel 'Hijack' In Surgical Gown Case
• 'Lack Of Clairvoyance' On Tax Audit Isn't Fraud, Perrigo Says
• Takeda Says Orexigen's Ch. 11 Plan Exposes It To $6M Claim
• Methods For Using Natural Compounds Can Be Patent-Eligible
• GNC Misleads Consumers On FDA Approval, Suit Says
• BioScrip To Pay $1M To End Probe Into Unauthorized Refills
• An Overview Of The Debate Over Litigation Finance Disclosure
• J&J Says Investors' Baby Powder Claims Already Disproven
• Law360 Reveals Titans Of The Plaintiffs Bar
• Rockford, Ill., Drug Antitrust Suit Beats Renewed Challenge
• One Sentence Ends Amgen Blockbuster's Reign, Judge Says
• St. Jude's Heart Valve Patent Challenges Get Mixed Results
• Alifax Wins $6.5M In Dispute Over Blood Testing Trade Secret
• Conviction Of Insys Execs Will Embolden Gov't In Opioid Fight
• Magistrate Details 'Cautionary Tale' Of Case-Ending Fraud
• Abbvie Investor Seeks Records On Alleged Humira Kickbacks
• Stryker Corp. Says XL Can't Blame Judge For Settlement
• Colgate Rips 'Disparaging' Sanctions Bid In ERISA Suit
• 16 Firms To Steer Packed Lineup Of IPOs Dominated By Uber
• Allergan Says Drug Buyers Trying To Delay Case 'Indefinitely'
• VA Misled Losing Bidder In Talks Over $22.6M Deal
• 2 New Efforts To Clarify Employee Cannabis Drug Testing
• DLA Piper Snags SF Real Estate Partner From Paul Hastings
• Recently Confirmed Judge Up For 3rd Circ. Promotion
• Fed. Circ. Upholds Opana Patent Amid Generic Challenge
• Supplement Co. Says FDA Crackdown On Stimulant Unlawful
• Abraham, Entwistle Seek $5.6M Atty Fees For Alere Deal
• Gene Therapy Policies Can Strike An Ethical Balance
• Obviousness Analysis Trends In Pharma Patent Cases
• Deals Rumor Mill: SoftBank, Louis Dreyfus, Shell
• GlaxoSmithKline Hit With $89.7M Verdict For Inhaler IP
• Merck Sues To Nix Mylan's Plans For Diabetes Generic
• States Say They Can Show Conspiracy In Generic Drug MDL
• New FDA Boss Details Wide-Ranging Enforcement Plan
• FDA Won't Ban Breast Implants Linked To Cancer
• Sheppard Mullin Snags Knobbe Martens Life Sciences IP Duo
• 1 Firm Edges Ahead Of Peers In Resurgent April For IPOs
• Minerva's Retrial Bid Nixed In NovaSure Patent Fight
• Hospital Won't Get Redo In Suit Clearing Generic Pepcid
• Eisai Wants Aurobindo's Generic Weight Loss Drug Blocked
• Deadline Won't Stop Med Mal Suit Against Quest Diagnostics
• Ex-NECC Pharmacists Guilty Of Role In Fake Shipments
• Ex-Insys Execs Found Guilty In RICO Opioid Bribe Scheme
• Franchising In The Cannabis Industry Begins To Light Up
• McKesson Pays $37M To Settle West Virginia's Opioid Suit
• A Tool For Budgeting Corporate Innovation Programs
• How To Identify And Deal With Narcissists In Law
• Clint Eastwood's Patent Investments Suit Tossed For Now
• Fed. Circ. Backs ITC's Refusal To Probe False Ad Claims
• Fed. Circ. OKs 'Unusual' $1.3M Fees Bill On Failed IP Suit
• SEC Must Decide On Teva Whistleblower Award, DC Circ. Told
• Judge Says TridentUSA Ch. 11 Plan OK If Probe Info Added
• Insys Jury Question Could Indicate Conviction On The Way
• Ocular Shakes Investor Suit Over FDA Approval Of Eye Drug
• PTAB Axes Another Antecip Bone Treatment Patent
• Pharma Co. Says Bidders Showing Interest In Ch. 11 Sale